Abbott announced the closing of its $23 billion acquisition of Exact Sciences after securing regulatory approvals and shareholder consent, moving the company deeper into cancer screening and molecular diagnostics. Exact’s portfolio — including Cologuard, Oncotype DX, and multi‑cancer early detection assays — supplements Abbott’s diagnostics business and is expected to add roughly $3 billion in sales in 2026. Abbott framed the acquisition as accelerating growth in one of healthcare’s fastest‑growing segments and strengthening its position in population screening and precision diagnostics.